Aravive Investor Presentation Deck

Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers • 43 subjects participated; 42 dosed Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs Phase 1b ascending dose study in Platinum-Resistant Ovarian Cancer (PROC) No anti-drug antibodies (ADA) 10 mg/kg (IV) administered every other week suppressed serum GAS6 levels for 2 weeks • 53 patients with PROC in Phase 1b trial Batiraxcept generally well-tolerated across all doses • No dose-limiting toxicities • No discontinuations due to AEs i • No unexpected safety signals; safety profile consistent with PLD or PAC No ADA # PLATINUM RESISTANT OVARIAN CANCER Infusion-related reactions noted; managed with premedication regimen Exposure-response relationship at 10 mg/kg Batiraxcept 10 mg/kg + PAC (N=16) Batiraxcept 10 mg/kg + PLD Batiraxcept 15 mg/kg + PAC (N=3) Batiraxcept 15 mg/kg + PLD (N=2) Batiraxcept 20 mg/kg + PAC Batiraxcept 20 mg/kg + PLD (N=3) Batiraxcept IV q14 days: Pegylated liposomal doxorubicin (PLD) 40 mg/m² d1 of 28-day cycle, Paclitaxel (PAC) 80 mg/m² day 1, day 8, day 15 of 28-day cycle: Maintenance dosing on batraxcept monotherapy 13

View entire presentation